

Patent
Attorney Docket No. 032751-052

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Jean-Marc Balloul et al.

Group Art Unit: 1648

Application No.: 09/832,899

Examiner: Timothy M. Brown

Filing Date: April 12, 2001

Confirmation No.: 1686

Title: POXVIRUS WITH TARGETED INFECTION SPECIFICITY

**SECOND
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a **SECOND** Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.


- ☐ No additional fee for submission of an IDS is required.
- ☒ The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☒ A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge _____ to Deposit Account No. 02-4800 for the fee due.
- ☒ A check in the amount of \$ 180.00 is enclosed for the fee due.
- ☐ Charge _____ to credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.


Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

By 
Deborah H. Yellin
Registration No. 45,904

Date: April 11, 2005



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
)
Jean-Marc Balloul et al.) Group Art Unit: 1648
)
Application No.: 09/832,899) Examiner: Timothy M. Brown
)
Filed: April 12, 2001) Confirmation No.: 1686
)
For: POXVIRUS WITH TARGETED)
INFECTION SPECIFICITY)

SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.
A fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is enclosed.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

04/13/2005 MBEYENE1 00000036 09832899

01 FC:1806

180.00 0P

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date April 11, 2005

By: 

Deborah H. Yellin
Registration No. 45,904

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

VA 727431.1


FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	09/832,899
Filing Date	April 12, 2001
First Named Inventor	Jean-Marc Balloul
Examiner Name	Timothy M. Brown
Attorney Docket Number	032751-052



U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	KIANMANESH et al., "A "Distant" Bystander Effect of Suicide Gene Therapy: Regression of Nontransduced Tumors Together with a Distant Transduced Tumor", <i>Human Gene Therapy</i> , October 10, 1997, 8:1807-1814, Mary Ann Liebert, Inc., Larchmont, New York.
	ADACHI et al., "Experimental Gene Therapy for Brain Tumors Using Adenovirus-Mediated Transfer of Cytosine Deaminase Gene and Uracil Phosphoribosyltransferase Gene with 5-Fluorocytosine", <i>Human Gene Therapy</i> , January 1, 2000, 11:77-89, Mary Ann Liebert, Inc., Larchmont, New York.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.